Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder : A Systematic Review of Randomized Clinical Trials
Copyright © 2020, Parvataneni et al..
Melatonin is a hormone produced by the pineal gland and is available over the counter for treating sleep problems in the pediatric population. We conducted a systematic review of randomized clinical trials (RCTs) on MEDLINE and included six studies that met our inclusion criteria. RCTs were conducted in patients from two to 18 years of age with a diagnostic and statistical manual of mental disorders (DSM)-IV diagnosis of autism spectrum disease (ASD) and/or attention-deficit hyperactivity disorder (ADHD) in both short-term and long-term RCTs ranging from eight-week to 52-week studies. The mean difference in the children's sleep disorder showed statistically significant improvement in sleep duration and sleep latency onset compared to the placebo. Overall, a high response rate was observed in the melatonin group compared to the placebo in treating sleep problems in children. Melatonin is a well-tolerated and safe medication in the dose range of 2-10 mg/day in the child and adolescent population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cureus - 12(2020), 5 vom: 28. Mai, Seite e8335 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parvataneni, Tarun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Child and adolescent psychiatry |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.8335 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311949894 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311949894 | ||
| 003 | DE-627 | ||
| 005 | 20231225143344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.8335 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311949894 | ||
| 035 | |a (NLM)32617211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parvataneni, Tarun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder |b A Systematic Review of Randomized Clinical Trials |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020, Parvataneni et al. | ||
| 520 | |a Melatonin is a hormone produced by the pineal gland and is available over the counter for treating sleep problems in the pediatric population. We conducted a systematic review of randomized clinical trials (RCTs) on MEDLINE and included six studies that met our inclusion criteria. RCTs were conducted in patients from two to 18 years of age with a diagnostic and statistical manual of mental disorders (DSM)-IV diagnosis of autism spectrum disease (ASD) and/or attention-deficit hyperactivity disorder (ADHD) in both short-term and long-term RCTs ranging from eight-week to 52-week studies. The mean difference in the children's sleep disorder showed statistically significant improvement in sleep duration and sleep latency onset compared to the placebo. Overall, a high response rate was observed in the melatonin group compared to the placebo in treating sleep problems in children. Melatonin is a well-tolerated and safe medication in the dose range of 2-10 mg/day in the child and adolescent population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a child and adolescent psychiatry | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a insomnia | |
| 650 | 4 | |a melatonin | |
| 650 | 4 | |a ramelteon | |
| 650 | 4 | |a rct | |
| 650 | 4 | |a safety study | |
| 650 | 4 | |a sleep problems | |
| 700 | 1 | |a Srinivas, Sushma |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Kaushal |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Rikinkumar S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 12(2020), 5 vom: 28. Mai, Seite e8335 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:5 |g day:28 |g month:05 |g pages:e8335 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.8335 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 5 |b 28 |c 05 |h e8335 | ||